Do you have Narcolepsy? Interested in participating in a clinical trial?

Lemborexant in Delayed Sleep Phase Syndrome

Purpose: Stanford has partnered with Eisai and UCSF to explore the potential benefits of Lemborexant, a melatonin agonist used to treat insomnia, in Delayed Sleep Phase Syndrome. Stanford will recruit 30 participants to participate in a 6-week trial to evaluate and safety and efficacy of Lemborexant.


  • Must be at least 18 years old
  • Must meet the criteria of delayed sleep phase syndrome


  • Uncontrolled/untreated clinically significant psychiatric or medical disorders
  • Pregnant or trying to become pregnant
  • Impaired organ function
  • Shift workers subject to unusual hours
  • Known to be human immunodeficiency virus positive
  • Use of medication with significant effects on sleep wake function ( stimulants, insomnia therapies, etc.)

Time commitment: The trial period includes 4 study visits over 6 weeks at Stanford Redwood City Sleep Clinic and a 2-week treatment phase where participants will have equal chances of receiving treatment or placebo. Participants will be compensated up to $1,280 for their time and effort.

Coordinator Contact: Sara Lomba